DEA Streamlines Process for Expanding Clinical Trials of Marijuana Extract Cannabidiol

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson Controlled Substances Module, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Clinical Trials

DEA Streamlines Process for Expanding Clinical Trials of Marijuana Extract Cannabidiol

Joan Flynn

December 23, 2015 at 06:13:00 ET

The Drug Enforcement Administration has streamlined the process for expanding clinical trials of the marijuana plant extract cannabidiol (CBD) and has notified affected researchers of the change by letter, the agency announced Dec. 23. DEA said it had eased some of the regulatory requirements imposed by the Controlled Substances Act to help foster ongoing studies of the possible m... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Controlled Substances’ Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the Controlled Substances Module.

Subscription Benefits

Start Your Free Trial

DEA Streamlines Process for Expanding Clinical Trials of Marijuana Extract Cannabidiol

My Research Folders

THOMPSON CONTROLLED SUBSTANCES

COMPLIANCE EXPERT

DEA RESOURCES

HELP

CONTACT